GATA
Etude de la combinaison de l'Atezolizumab avec le Venetoclax et l'Obinutuzumab dans les lymphomes B en rechute ou réfractaire (phase Ib-II) rechute ou réfractaire (phase Ib-II)Plaquette
| Poster GATA | ASCO 2020 |
|---|---|
| C Herbaux | Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R/R DLBCL): Primary analysis of a phase II trial from LYSA |
| Communication orale GATA | EHA 2020 |
|---|---|
| C Herbaux | Efficacy and Safety of Atezolizumab + Obinutuzumab + Venetoclax in patients with relapsed or refractory Diffuse Large B-Cell Lymphomas: Primary analysis of a Phase 2 trial from LYSA
|
